POSSIBILITIES FOR PREVENTING EXACERBATIONS OF CHRONIC RESPIRATORY DISEASES
Ключевые слова:
chronic bronchopulmonary pathology, chronic obstructive pulmonary disease, bronchial asthma, chronic bronchitis, community-acquired pneumonia, antibiotic resistance.Аннотация
Control of virus-induced inflammation of the respiratory tract in patients with chronic bronchopulmonary pathology remains an urgent medical task. Management of the immune response in case of acute respiratory viral infection (ARVI) in such patients seems to be one of the promising areas. This review summarizes the results of observational programs and initiative studies demonstrating the experience of using a drug based on technologically processed antibodies, which has an immune-mediated antiviral and antibacterial effect, in patients in pulmonology practice. The mechanism of action of the drug is associated with the activation of antigen processing and presentation with the participation of molecules of the major histocompatibility complex, which in turn contributes to the formation of an adequate immune response in the infectious process, which determines the possibility of its use in the treatment of ARVI in patients at risk of an unfavorable course of respiratory infection.
Библиографические ссылки
Chronic obstructive pulmonary disease (COPD) – key facts. (Electronic resource.) URL: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) (date of access: 06.07.2023).
Immunomodulators Market Analysis, By Product (Immunosuppressants, Immunostimulants, Antibodies), By Application (Oncology, Respiratory, HIV, Others), Forecast To 2027. Accessed February 14, 2022. (Electronic resource.) URL: https://www .reportsanddata.com/report-detail/immunomodulators-market (access date: 06/07/2023).
General pharmacopoeial article of the State Pharmacopoeia of the Russian Federation, XV edition, OFS. 1.7.0001 Biological medicinal products obtained by gradual technology. Date of introduction: 01.09.2023. (Electronic resource.) URL: https://pharmacopoeia.regmed.ru/pharmacopoeia/izdanie-15/1/1-9/biologicheskie-lekarstvennye-preparat. gradualnoy-tekhnologii/ (date of access: 06.07.2023).
Active ingredients: modified affinity purified antibodies to human interferon γ, to CD4, to β2-microglobulin MHC class I and to the β1-domain of MHC class II.
Development of the COVID-19 infection model: a preclinical study of a new drug Rafamin. (Electronic resource.) URL: https://www.vibiosphen.com/development-covid-19-infection-model-preclinical-study-new-drug-rafamin (access date: 07/06/2023).
Strategy for control of antimicrobial therapy. (Electronic resource.) URL: http://nasci.ru/?id=2880 (date of access: 06.07.2023).
Clinical guidelines. Community-acquired pneumonia in adults. M.; 2021. (Electronic resource.) URL: https://cr.minzdrav.gov.ru/schema/654_1 (date accessed: 06.07.2023).
Clinical trials of the drug Rafamin, registered on the international clinical trials portal ClinicalTrials.gov (Electronic resource.) URL: https://classic.clinicaltrials.gov/ct2/results?cond=&term=raphamin&cntry=&state=&city=&dist= (date accessed: 06.07.2023).
